Radically accelerating immunotherapy

RootPath is a Cambridge-based biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. Our next generation technologies allow us to precisely monitor, modulate and steer the immune system for a revolution in the diagnosis and treatment of cancer.

 

Our focus

RootPath is focused on the analysis and manipulation of single immune cells in order to enable next-generation immune- and cell-therapy.

While the immune system is the most powerful killing system in our body, we can’t fully mobilize it without a more complete understanding of how it works and a more sophisticated way to give it orders. Just as the development of genomic technologies coincided and led to the blossoming of targeted therapy, we believe the development of immunological technologies will coincide and lead to the blossoming of immunotherapy.

We are developing technologies that enable improved strength of the immune system, speed of analysis and manipulation of cells and specificity toward disease.

 

Team

RootPath was founded by scientists and bioengineers instrumental in the development of synthetic biology, genome engineering and single-cell sequencing technologies. Our team is international, interdisciplinary and highly accomplished in many areas of biotechnology.

Screenshot 2018-08-09 10.09.54.png
Xi Chen
Co-Founder & CEO
Yinqing Li
Co-founder & Scientific Advisor
563a90b6-74b9-4da2-ab26-cd97d6096fca-1.j
丛乐形象照.jpg
Le Cong
Co-founder & Scientific Advisor
Screenshot 2018-08-09 10.07.20.png
Ely Porter
Co-founder & Lead Scientist
Cheryl Cui
Co-Founder
 
 
Contact
RootPath Genomics
65 Grove Street
Suite 203
Watertown, MA 02472

Join our team

Contact
RootPath Genomics | 325 Vassar St | Cambridge, MA 02139 | USA